Idecabtagene vicleucel: clinical use

Prescribing considerations

• Restrict use to qualified centres with trained staff, emergency facilities and appropriate treatment for cytokine release syndrome immediately available.
• Confirm patient identity against every patient-specific bag and accompanying release documentation.
• Assess whether rapid disease progression could prevent delivery of the manufactured product.
• Screen for CMV, HBV, active HCV and active HIV before cell collection.
• Review cardiac, pulmonary, renal, hepatic and neurological status and ensure serious preceding toxicities have resolved.
• Maintain long-term traceability and lifelong surveillance for secondary malignancy.

Contraindications and cautions

• Hypersensitivity to idecabtagene vicleucel or an excipient.
• Consider any contraindication to preparative lymphodepleting chemotherapy.
• Delay infusion with active infection or inflammatory disease, unresolved serious toxicity or active graft-versus-host disease.
• Use particular caution with clinically significant CNS disease or inadequate renal, hepatic, pulmonary or cardiac function.

Monitoring

• Monitor closely for cytokine release syndrome and neurological toxicity, with continued access to urgent specialist assessment.
• Monitor full blood count for prolonged cytopenias and assess promptly for febrile neutropenia or infection.
• Monitor immunoglobulins and manage hypogammaglobulinaemia and infection risk according to local protocols.
• Monitor for CMV and other viral reactivation where clinically indicated.
• Continue lifelong monitoring for secondary malignancies, including T-cell malignancy.

Clinical pharmacology

Autologous T cells are transduced ex vivo with a lentiviral vector encoding an anti-BCMA CAR containing CD3-zeta signalling and 4-1BB costimulatory domains. BCMA binding triggers T-cell activation, expansion, cytokine release and cytolytic killing; modified cells may persist in peripheral blood.

Formulation and product differences

• Patient-specific, colourless cell dispersion supplied frozen in one or more infusion bags with a batch-dependent cell concentration.
• Contains DMSO and clinically relevant amounts of sodium and potassium; consider hypersensitivity, renal function and controlled electrolyte diets.
• For intravenous use only; do not mix with other medicines or administer through a leukodepleting filter.